Related Experiment Video
Updated: Jul 9, 2026

A Comprehensive Procedure to Evaluate the In Vivo Performance of Cancer Nanomedicines
Published on: March 4, 2017
Nanomedicine and risk: further perspectives
1The Institute of Nanotechnology, Stirling, UK. richard.moore@nano.org.uk
Abstract:
The first article in this new series on nanomedicine, advocated the need for more risk research in the field of medical nanotechnology. Here, some further aspects of risk at the nanoscale are considered and suggestions are made on where this risk effort should be focused.
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacogenomics: Identification of New Drug Targets
Drug Toxicity: Risk factors
Pharmacogenetics and Pharmacogenomics: Overview
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
